New drug aims to shrink brain tumors by blocking cancer's growth signal
NCT ID NCT04197934
First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 4 times
Summary
This early-phase trial tests a drug called WSD0922-FU in 56 people with certain brain cancers (glioblastoma, anaplastic astrocytoma) or lung cancer that has spread to the brain or spinal cord. The drug blocks a protein called EGFR that helps cancers grow, and is designed to reach tumors in the central nervous system. The main goals are to find the best dose and check for side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAPLASTIC ASTROCYTOMA, IDH-WILDTYPE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259, United States
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Facing the fear: a new program aims to ease anxiety in advanced cancer
- Can a Chemo-Immunotherapy duo outsmart tough lung cancer?
- New drug combo targets Hard-to-Treat brain tumors
- Wheat germ supplement studied for immune boost in advanced cancer
- Laser zaps brain tumor, then immunotherapy fights back: new hope for glioblastoma?
- Lab test aims to match brain tumor patients with targeted drugs